[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
Published in Science Advances: the preclinical development program of exoASO-STAT6, a novel, engineered #exosome precision medicine candidate for the treatment of macrophage-rich tumors.
Early/ late resistance marker; Immunological profile; NGS; Non small-cell lung cancer; Pancreatic ductal adenocarcinoma; Triple negative breast or Luminal Breast Cancer.
SARS-CoV-2; antiviral drug combination; hepatitis C virus; hepatitis E virus; human immunodeficiency virus; influenza A virus; interferon-alpha.
SARS-CoV-2; interferon-alpha; nafamostat; antiviral drug combination; broad-spectrum antivirals
SARS-CoV-2; antiviral drug combination; broad-spectrum antivirals; interferon-alpha; nafamostat.
Hypoxia; Lung fibrosis; PET/CT; [18F]FDG; [18F]FMISO.
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
Read in Communication Biologics (Nature), the data from the exoSTING preclinical program, in which Oncodesign participated (Hepa1-6).
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection